Emerging vectors and targeting methods for nonviral gene therapy
- 29 August 2006
- journal article
- review article
- Published by Informa Healthcare in Emerging Drugs
- Vol. 11 (3), 541-557
- https://doi.org/10.1517/14728214.11.3.541
Abstract
Until recently, nonviral vectors were outside the mainstream of gene transfer technology. Recent problems in clinical trials using viral vectors renewed interest in these methods. The clinical usefulness of nonviral methods is still hindered by their relatively low gene delivery/transgene expression efficiencies. Vectors must navigate a series of obstacles before the therapeutic gene can be expressed. This review considers these barriers and the properties of components of nonviral vectors that are essential for nucleic acid transfer. Although developments of new physical methods (hydrodynamic delivery, ultrasound, electroporation) have made a significant impact on gene transfer efficiency, various chemical carriers (lipids and polymers) have been shown to achieve high-level gene delivery and functional expression. Success of nonviral gene targeting will depend not only on the efficacy, but also safety of this methodology, and this aspect is also discussed. Understanding problems associated with nonviral targeting can also help in designing better viral vectors. In fact, interplay between viral and nonviral technologies should lead to a continued refinement of both methodologies.Keywords
This publication has 100 references indexed in Scilit:
- Characterization of immune response in mice to plasmid DNA encoding human sperm associated antigen 9 (SPAG9)Vaccine, 2006
- Short and highly efficient synthetic promoters for melanoma‐specific gene expressionFEBS Letters, 2004
- A synthetic peptide containing loop 4 of nerve growth factor for targeted gene deliveryThe Journal of Gene Medicine, 2004
- Extracellular and intracellular barriers in non-viral gene deliveryJournal of Controlled Release, 2003
- Transcutaneous Ultrasound Augments Naked DNA Transfection of Skeletal MuscleMolecular Therapy, 2002
- Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoterCancer Gene Therapy, 2000
- Direct Immunologic activities of CpG DNA and implications for gene therapyThe Journal of Gene Medicine, 1999
- Coupling of cell-binding ligands to polyethylenimine for targeted gene deliveryGene Therapy, 1997
- Age and sex influence expression of plasmid DNA directly injected into mouse skeletal muscleFEBS Letters, 1992
- The neuroleptic activity of haloperidol increases after its solubilization in surfactant micellesFEBS Letters, 1989